202 related articles for article (PubMed ID: 15597072)
21. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control.
Thornton V; Lennon D; Rasanathan K; O'Hallahan J; Oster P; Stewart J; Tilman S; Aaberge I; Feiring B; Nokleby H; Rosenqvist E; White K; Reid S; Mulholland K; Wakefield MJ; Martin D
Vaccine; 2006 Feb; 24(9):1395-400. PubMed ID: 16242221
[TBL] [Abstract][Full Text] [Related]
22. Meningococcal B immunisation in New Zealand: why haven't we seen the data?
Bolland M
N Z Med J; 2008 Mar; 121(1270):107-9. PubMed ID: 18364764
[No Abstract] [Full Text] [Related]
23. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand.
Oster P; O'Hallahan J; Aaberge I; Tilman S; Ypma E; Martin D
Vaccine; 2007 Apr; 25(16):3075-9. PubMed ID: 17289223
[TBL] [Abstract][Full Text] [Related]
24. Meningococcal C vaccines: the Canadian experience.
De Wals P
Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
[TBL] [Abstract][Full Text] [Related]
25. The risk of simple febrile seizures after immunisation with a new group B meningococcal vaccine, New Zealand.
Stehr-Green P; Radke S; Kieft C; Galloway Y; McNicholas A; Reid S
Vaccine; 2008 Feb; 26(6):739-42. PubMed ID: 18187240
[TBL] [Abstract][Full Text] [Related]
26. Getting to grips with an epidemic.
Desmond N
Nurs N Z; 2004 Aug; 10(7):2. PubMed ID: 15460638
[No Abstract] [Full Text] [Related]
27. Recent developments in vaccines to prevent meningococcal serogroup B infections.
Vermont CL; van den Dobbelsteen GP; de Groot R
Curr Opin Mol Ther; 2003 Feb; 5(1):33-8. PubMed ID: 12669468
[TBL] [Abstract][Full Text] [Related]
28. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain.
Oster P; Lennon D; O'Hallahan J; Mulholland K; Reid S; Martin D
Vaccine; 2005 Mar; 23(17-18):2191-6. PubMed ID: 15755593
[TBL] [Abstract][Full Text] [Related]
29. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate.
Delgado M; Yero D; Niebla O; González S; Climent Y; Pérez Y; Cobas K; Caballero E; García D; Pajón R
Vaccine; 2007 Dec; 25(50):8420-31. PubMed ID: 17996338
[TBL] [Abstract][Full Text] [Related]
30. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
Pace D
Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific serogroup B meningococcal vaccine given to preteens.
Hosking J; Rasanathan K; Mow FC; Jackson C; Martin D; O'Hallahan J; Oster P; Ypma E; Reid S; Aaberge I; Crengle S; Stewart J; Lennon D
Clin Vaccine Immunol; 2007 Nov; 14(11):1393-9. PubMed ID: 17898183
[TBL] [Abstract][Full Text] [Related]
32. Successful intervention in a group A meningococcal outbreak in Auckland, New Zealand.
Lennon D; Gellin B; Hood D; Voss L; Heffernan H; Thakur S
Pediatr Infect Dis J; 1992 Aug; 11(8):617-23. PubMed ID: 1523071
[TBL] [Abstract][Full Text] [Related]
33. Re: Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5 year olds in New Zealand, Oster P, O'Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D. Vaccine 2007;25(16):3075-9.
Lennon D
Vaccine; 2007 Sep; 25(39-40):6835; author reply 6835-6. PubMed ID: 17875437
[No Abstract] [Full Text] [Related]
34. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak.
Caron F; du Châtelet IP; Leroy JP; Ruckly C; Blanchard M; Bohic N; Massy N; Morer I; Floret D; Delbos V; Hong E; Révillion M; Berthelot G; Lemée L; Deghmane AE; Bénichou J; Lévy-Bruhl D; Taha MK
Lancet Infect Dis; 2011 Jun; 11(6):455-63. PubMed ID: 21489881
[TBL] [Abstract][Full Text] [Related]
35. Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks.
Taha MK; Zarantonelli ML; Alonso JM; Naess LM; Holst J; Feiring B; Rosenqvist E
Vaccine; 2007 Mar; 25(14):2537-8. PubMed ID: 16460845
[No Abstract] [Full Text] [Related]
36. Reducing inequalities with vaccines: New Zealand's MeNZB vaccine initiative to control an epidemic.
Lennon D; Reid S; Stewart J; Jackson C; Crengle S; Percival T
J Paediatr Child Health; 2012 Mar; 48(3):193-201. PubMed ID: 21996021
[TBL] [Abstract][Full Text] [Related]
37. Challenges and progress in the development of a serogroup B meningococcal vaccine.
Lewis S; Sadarangani M; Hoe JC; Pollard AJ
Expert Rev Vaccines; 2009 Jun; 8(6):729-45. PubMed ID: 19485754
[TBL] [Abstract][Full Text] [Related]
38. Proceedings of the Meningococcal Vaccine Strategy World Health Organization satellite meeting, 10 March 2004, Auckland, New Zealand.
Sexton K; Lennon D; Oster P; Aaberge I; Martin D; Reid S; Wong S; O'Hallahan J
N Z Med J; 2004 Aug; 117(1200):1 p preceding U1027. PubMed ID: 15481128
[TBL] [Abstract][Full Text] [Related]
39. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada.
Bettinger JA; Scheifele DW; Le Saux N; Halperin SA; Vaudry W; Tsang R;
Pediatr Infect Dis J; 2009 Mar; 28(3):220-4. PubMed ID: 19209096
[TBL] [Abstract][Full Text] [Related]
40. Epidemiology and prevention of meningococcal disease: a critical appraisal of vaccine policies.
Sáfadi MA; McIntosh ED
Expert Rev Vaccines; 2011 Dec; 10(12):1717-30. PubMed ID: 22085175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
